Genetic regulation of gene expression of MIF family members in lung tissue

Laura Florez-Sampedro, Corry-Anke Brandsma, Maaike de Vries, Wim Timens, Rene Bults, Cornelis J Vermeulen, Maarten van den Berge, Ma'en Obeidat, Philippe Joubert, David C Nickle, Gerrit J Poelarends, Alen Faiz, Barbro N Melgert, Laura Florez-Sampedro, Corry-Anke Brandsma, Maaike de Vries, Wim Timens, Rene Bults, Cornelis J Vermeulen, Maarten van den Berge, Ma'en Obeidat, Philippe Joubert, David C Nickle, Gerrit J Poelarends, Alen Faiz, Barbro N Melgert

Abstract

Macrophage migration inhibitory factor (MIF) is a cytokine found to be associated with chronic obstructive pulmonary disease (COPD). However, there is no consensus on how MIF levels differ in COPD compared to control conditions and there are no reports on MIF expression in lung tissue. Here we studied gene expression of members of the MIF family MIF, D-Dopachrome Tautomerase (DDT) and DDT-like (DDTL) in a lung tissue dataset with 1087 subjects and identified single nucleotide polymorphisms (SNPs) regulating their gene expression. We found higher MIF and DDT expression in COPD patients compared to non-COPD subjects and found 71 SNPs significantly influencing gene expression of MIF and DDTL. Furthermore, the platform used to measure MIF (microarray or RNAseq) was found to influence the splice variants detected and subsequently the direction of the SNP effects on MIF expression. Among the SNPs found to regulate MIF expression, the major LD block identified was linked to rs5844572, a SNP previously found to be associated with lower diffusion capacity in COPD. This suggests that MIF may be contributing to the pathogenesis of COPD, as SNPs that influence MIF expression are also associated with symptoms of COPD. Our study shows that MIF levels are affected not only by disease but also by genetic diversity (i.e. SNPs). Since none of our significant eSNPs for MIF or DDTL have been described in GWAS for COPD or lung function, MIF expression in COPD patients is more likely a consequence of disease-related factors rather than a cause of the disease.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Schematic representation of the lung tissue dataset and methods used in our study. The total lung tissue dataset (n = 1087) was used for the eQTL analysis and a subset of COPD patients (n = 276) and matched non-COPD subjects (n = 236) from the same dataset was used for the gene expression analysis, comparing expression levels of MIF, DDT and DDTL. *DNA was isolated from blood samples in the Laval cohort and from lung tissue samples in the Groningen and British Columbia cohorts.
Figure 2
Figure 2
MIF, DDT and DDTL expression in lung tissue from COPD and non-COPD patients. Gene expression profiles for MIF (A), DDT (B) and DDTL (C) were obtained using a custom Affymetrix array (see GEO platform GPL10379), using 276 samples of COPD patients and 236 samples of non-COPD subjects, from the lung tissue database. Units of gene expression (y axis) represent Log2(microarray intensity) units. Data are presented as box and whiskers plots of the 5–95 percentile with median. Statistical differences were tested with Mann Whitney test.
Figure 3
Figure 3
eQTL analysis and main results. (A) Schematic representation of the methodology used for the eQTL analysis, subsequent analyses and their corresponding main results. (B) eQTL result for rs5751777. Effect of the rs5751777 genotype on MIF and DDTL expression levels in lung tissue samples from the lung tissue dataset (n = 1087). Data are presented as mean ± standard error of the mean.
Figure 4
Figure 4
MIF splice variants and binding site of Affymetrix MIF probe. (A) Graphic representation of MIF and its splice variants. (B) Sequence and binding site of Affymetrix probes for MIF.
Figure 5
Figure 5
Schematic representation of the airway wall biopsy dataset and methods used in our study. The airway wall biopsy dataset was used for the splice QTL analysis and cis-eQTL analysis in the same dataset. In the current study only results for rs5751777 are shown.
Figure 6
Figure 6
Effect of rs5751777 on expression of MIF splice variants and on total MIF. (A) SpliceQTL results. Split read counts mapping across exon–exon junction according to rs5751777 genotype. The number of split reads of a given junction pair was normalized per sample by correcting for variation in library size and transcript abundance in a gene-wise fashion. (B) Effect of rs5751777 on normalized MIF expression, represented as fragments per kilobase of exon model per million reads mapped (FPKM). Graphs are presented as mean ± standard error of the mean.

References

    1. Sparkes A, et al. Reprint of: The non-mammalian MIF superfamily. Immunobiology. 2017;222:858–867. doi: 10.1016/j.imbio.2017.05.004.
    1. Jankauskas SS, Wong DWL, Bucala R, Djudjaj S, Boor P. Evolving complexity of MIF signaling. Cell. Signal. 2019;57:76–88. doi: 10.1016/j.cellsig.2019.01.006.
    1. Eickhoff R, et al. Purification and characterization of macrophage migration inhibitory factor as a secretory protein from rat epididymis: evidences for alternative release and transfer to spermatozoa. Mol. Med. 2001;7:27–35. doi: 10.1007/BF03401836.
    1. Kapurniotu A, Gokce O, Bernhagen J. The multitasking potential of alarmins and atypical chemokines. Front. Med. 2019;6:3. doi: 10.3389/fmed.2019.00003.
    1. Leyton-Jaimes MF, Kahn J, Israelson A. Macrophage migration inhibitory factor: a multifaceted cytokine implicated in multiple neurological diseases. Exp. Neurol. 2018;301:83–91. doi: 10.1016/j.expneurol.2017.06.021.
    1. Sauler M, Bucala R, Lee PJ. Role of macrophage migration inhibitory factor in age-related lung disease. Am. J. Physiol. Cell. Mol. Physiol. 2015;309:L1–L10. doi: 10.1152/ajplung.00339.2014.
    1. Tilstam PV, Qi D, Leng L, Young L, Bucala R. MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics. Expert Opin. Ther. Targets. 2017;21:671–683. doi: 10.1080/14728222.2017.1336227.
    1. Nobre CCG, et al. Macrophage migration inhibitory factor (MIF): biological activities and relation with cancer. Pathol. Oncol. Res. 2017;23:235–244. doi: 10.1007/s12253-016-0138-6.
    1. Florez-Sampedro L, Soto-Gamez A, Poelarends GJ, Melgert BN. The role of MIF in chronic lung diseases: looking beyond inflammation. Am. J. Physiol. Lung Cell. Mol. Physiol. 2020 doi: 10.1152/ajplung.00521.2019.
    1. Russell KE, et al. The MIF antagonist ISO-1 attenuates corticosteroid-insensitive inflammation and airways hyperresponsiveness in an ozone-induced model of COPD. PLoS ONE. 2016;11:e0146102. doi: 10.1371/journal.pone.0146102.
    1. Husebø GR, et al. Macrophage migration inhibitory factor, a role in COPD. Am. J. Physiol. Cell. Mol. Physiol. 2016;311:L1–L7. doi: 10.1152/ajplung.00461.2015.
    1. Fallica J, et al. Macrophage migration inhibitory factor is a novel determinant of cigarette smoke-induced lung damage. Am. J. Respir. Cell Mol. Biol. 2014;51:94–103. doi: 10.1165/rcmb.2013-0371OC.
    1. Sauler M, et al. Macrophage migration inhibitory factor deficiency in chronic obstructive pulmonary disease. Am. J. Physiol. Cell. Mol. Physiol. 2014;306:L487–L496. doi: 10.1152/ajplung.00284.2013.
    1. Baugh JA, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 2002;3:170–176. doi: 10.1038/sj.gene.6363867.
    1. Zhang C, et al. A functional macrophage migration inhibitory factor (MIF) promoter polymorphism is associated with reduced diffusing capacity. Am. J. Physiol. Cell. Mol. Physiol. 2018 doi: 10.1152/ajplung.00439.2018.
    1. Merk M, Mitchell RA, Endres S, Bucala R. D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. Cytokine. 2012;59:10–17. doi: 10.1016/j.cyto.2012.03.014.
    1. Bethesda (MD): National Library of Medicine (US), N. C. for B. I. Gene (2004) . Accessed 30th April 2020.
    1. Kok T, et al. Small-molecule inhibitors of macrophage migration inhibitory factor (MIF) as an emerging class of therapeutics for immune disorders. Drug Discov. Today. 2018;23:1910–1918. doi: 10.1016/j.drudis.2018.06.017.
    1. Nedeljkovic I, et al. Understanding the role of the chromosome 15q25.1 in COPD through epigenetics and transcriptomics. Eur. J. Hum. Genet. 2018;26:709–722. doi: 10.1038/s41431-017-0089-8.
    1. Brandsma C-A, et al. A large lung gene expression study identifying fibulin-5 as a novel player in tissue repair in COPD. Thorax. 2015;70:21–32. doi: 10.1136/thoraxjnl-2014-205091.
    1. Carithers LJ, et al. A novel approach to high-quality postmortem tissue procurement: the GTEx project. Biopreserv. Biobank. 2015;13:311–319. doi: 10.1089/bio.2015.0032.
    1. Faiz A, et al. Cigarette smoke exposure decreases CFLAR expression in the bronchial epithelium, augmenting susceptibility for lung epithelial cell death and DAMP release. Sci. Rep. 2018;8:12426. doi: 10.1038/s41598-018-30602-7.
    1. Damico R, et al. p53 mediates cigarette smoke-induced apoptosis of pulmonary endothelial cells: inhibitory effects of macrophage migration inhibitor factor. Am. J. Respir. Cell Mol. Biol. 2011;44:323–332. doi: 10.1165/rcmb.2009-0379OC.
    1. Lue H, et al. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 2007;26:5046–5059. doi: 10.1038/sj.onc.1210318.
    1. Hao K, et al. Lung eQTLs to help reveal the molecular underpinnings of asthma. PLoS Genet. 2012;8:e1003029. doi: 10.1371/journal.pgen.1003029.
    1. Pillai S, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009;5:e100421. doi: 10.1371/journal.pgen.1000421.
    1. Siedlinski M, et al. Genome-wide association study of smoking behaviours in patients with COPD. Thorax. 2011;66:894–902. doi: 10.1136/thoraxjnl-2011-200154.
    1. Cho M, et al. A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum. Mol. Genet. 2012;21:947–957. doi: 10.1093/hmg/ddr524.
    1. McDonald M, et al. Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2014;51:678–687. doi: 10.1165/rcmb.2014-0135OC.
    1. Smolonska J, et al. Common genes underlying asthma and COPD? Genome-wide analysis on the Dutch hypothesis. Eur. Respir. J. 2014;44:860–872. doi: 10.1183/09031936.00001914.
    1. Dijkstra A, et al. Dissecting the genetics of chronic mucus hypersecretion in smokers with and without COPD. Eur. Respir. J. 2015;45:60–75. doi: 10.1183/09031936.00093314.
    1. Hobbs B, et al. Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. Nat. Genet. 2017;49:426–432. doi: 10.1038/ng.3752.
    1. Sakornsakolpat P, et al. Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. Nat. Genet. 2019;51:494–505. doi: 10.1038/s41588-018-0342-2.
    1. Lutz S, et al. Common and rare variants genetic association analysis of cigarettes per day among ever-smokers in chronic obstructive pulmonary disease cases and controls. Nicotine Tob. Res. 2019;21:714–722. doi: 10.1093/ntr/nty095.
    1. Repapi E, et al. Genome-wide association study identifies five loci associated with lung function. Nat. Genet. 2010;42:36–44. doi: 10.1038/ng.501.
    1. Hancock D, et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat. Genet. 2010;42:45–52. doi: 10.1038/ng.500.
    1. Yao T, et al. Genome-wide association study of lung function phenotypes in a founder population. J. Allergy Clin. Immunol. 2014;133:248–255. doi: 10.1016/j.jaci.2013.06.018.
    1. Liao S, Lin X, Christiani D. Genome-wide association and network analysis of lung function in the Framingham Heart Study. Genet. Epidemiol. 2014;38:572–578. doi: 10.1002/gepi.21841.
    1. Lutz S, et al. A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry. BMC Genet. 2015;16:138. doi: 10.1186/s12863-015-0299-4.
    1. Soler Artigas M, et al. Sixteen New Lung Function Signals Identified Through 1000 Genomes Project Reference Panel imputation. Nat. Commun. 2015;6:8658. doi: 10.1038/ncomms9658.
    1. Wain L, et al. Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK biobank. Lancet Respir. Med. 2015;3:769–781. doi: 10.1016/S2213-2600(15)00283-0.
    1. de Jong K, et al. Genome-wide interaction study of gene-by-occupational exposure and effects on FEV1 levels. J. Allergy Clin. Immunol. 2015;136:1664–1672. doi: 10.1016/j.jaci.2015.03.042.
    1. de Jong K, et al. Genes and pathways underlying susceptibility to impaired lung function in the context of environmental tobacco smoke exposure. Respir. Res. 2017;18:142. doi: 10.1186/s12931-017-0625-7.
    1. Suh Y, Lee C. Genome-wide association study for genetic variants related with maximal voluntary ventilation reveals two novel genomic signals associated with lung function. Medicine (Baltimore) 2017;96:e8530. doi: 10.1097/MD.0000000000008530.
    1. Wyss A, et al. Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function. Nat. Commun. 2018;9:2976. doi: 10.1038/s41467-018-05369-0.
    1. Li X, et al. Genome-wide association study of lung function and clinical implication in heavy smokers. BMC Med. Genet. 2018;19:134. doi: 10.1186/s12881-018-0656-z.
    1. Shrine N, et al. New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. Nat. Genet. 2019;51:481–493. doi: 10.1038/s41588-018-0321-7.

Source: PubMed

3
Abonner